WHC is still in active development. Read this to understand our approach.
depiction of IMWZZHHPURKASS-UHFFFAOYSA-N.svg
tripsit

metaxalone

Check on tripsit

isomerdesign

Metaxalone

Check on isomerdesign

pubchem

Metaxalone

Check on pubchem

Data

InChI: InChI=1S/C12H15NO3/c1-8-3-9(2)5-10(4-8)15-7-11-6-13-12(14)16-11/h3-5,11H,6-7H2,1-2H3,(H,13,14)

Synonyms: METAXALONE [INN],Q6823309,5-((3,5-Dimethylphenoxy)methyl)-1,3-oxazolidin-2-one,A810747,AHR-438,HMS1922H07,SMR001821638,1NMA9J598Y,CCG-39592,CL 39,148,DSSTox_RID_76949,C07934,Metazalone,KBio3_002671,NCGC00095116-02,UNII-1NMA9J598Y,SPECTRUM1504229,WLN: T5MVOTJ D1OR C1 E1,EN300-119839,Spectrum4_000612,NSC-758703,Metaxalone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material,Metassalone [DCIT],METAXALONE [USP MONOGRAPH],1665-48-1,METAXALONE [MART.],Spectrum5_001685,Metaxalone, >=98% (HPLC),SCHEMBL34908,5-(3,5-dimethylphenoxymethyl)-2-oxazolidinone,Methaxalonum,AM20060525,METAXALONE [WHO-DD],.meta.Xalon,Metaxalone [USAN:INN:BAN],Metaxalon,Methoxolone,.meta.Zolone,BRD-A94709349-001-03-4,METAXALONE [VANDF],Z106952910,5-((3,5-Dimethylphenoxy)methyl)oxazolidin-2-one,GTPL7609,KBio2_002221,BRD-A94709349-001-02-6,.meta.Xalone,FT-0603568,skelaxin,5-[(3,5-dimethylphenoxy)methyl]oxazolidin-2-one,Spectrum3_001666,5-(3,5-Xyloloxymethyl)oxazolidin-2-one,CAS-1665-48-1,DB00660,SPBio_000595,2-Oxazolidinone,5-dimethylphenoxy)methyl]-,Metaxalonum [INN-Latin],KBioGR_001164,NCGC00095116-05,SR-05000001978,Zorane,Flexura,DSSTox_CID_3269,METAXALONE [MI],EINECS 216-777-6,SpecPlus_000656,s3730,NSC-170959,Tox21_111428_1,KBio2_004789,SR-05000001978-3,HY-B0678,5-[(3,5-Dimethylphenoxy)methyl]-2-oxazolidinone,DTXSID3023269,Metaxolone,METAXALONE [HSDB],CHEBI:6797,Tox21_111428,AHR438,2-Oxazolidinone, 5-[(3,5-xylyloxy)methyl]-,BSPBio_003451,MFCD00867700,Oprea1_438855,Metazolone,NCGC00095116-03,MLS003106749,Metaxalona [INN-Spanish],Pharmakon1600-01504229,Spectrum_001741,AB00053284_04,SR-05000001978-1,DB-043656,NSC758703,2-Oxazolidinone, 5-((3,5-xylyloxy)methyl)-,Metaxalona,5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one,5-[(3,5-Xylyloxy)methyl]-2-oxazolidinone,2-Oxazolidinone, 5-((3,5-dimethylphenoxy)methyl)-,BCP28377,CHEMBL1079604,KBio1_001696,NSC170959,STL450994,SBI-0052859.P002,D00773,DivK1c_006752,HMS2093C22,2-Oxazolidinone, 5-[(3,5-dimethylphenoxy)methyl]-,5-[(3,5-dimethylphenoxy)methyl]-4,5-dihydro-1,3-oxazol-2-ol,AKOS009035315,Metaxalone, United States Pharmacopeia (USP) Reference Standard,DSSTox_GSID_23269,KBio2_007357,METAXALONE [USAN],NSC 170959,Metaxalone (USP/INN),Metassalone,M2578,5-{[(3,5-dimethylphenyl)oxy]methyl}-1,3-oxazolidin-2-one,STL451511,Skelaxin,.meta.Zalone,FS-3218,5-((3,5-Xylyloxy)methyl)-2-oxazolidinone,BRN 0884592,AHR 438,Spectrum2_000548,665M481,Metaxalone,Metaxalona [Spanish],2-Oxazolidinone,5-xylyloxy)methyl]-,5-[(3,5-Dimethylphenoxy)methyl]-1,3-oxazolidin-2-one #,5-(3,5-dimethylphenoxymethyl)-1,3-oxazolidin-2-one,KBioSS_002221,Metaxalonum,METAXALONE [USP-RS],Metaxalone solution,5-(3,5-dimethylphenoxy)methyl-2-oxazolidinone,METAXALONE [ORANGE BOOK],Metaxalonum [Latin],J-010295,METAXALONE,SY052772,Skelaxin (TN),5-((3,5-Dimethylphenoxy)methyl)-2-oxazolidinone,NCGC00095116-01,HSDB 3236

Estimated data

Solubility: -2.602 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 40.0% (prediction based on www.mdpi.com)

Similarities

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.